Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Comment on "ALK is a therapeutic target for lethal sepsis".

Literature DB >> 30541790

Comment on "ALK is a therapeutic target for lethal sepsis".

Rafael B Blasco¹, Enrico Patrucco², Ines Mota², Wei-Tien Tai¹, Roberto Chiarle^3,2.

Abstract

Physiologically relevant ALK (anaplastic lymphoma kinase) expression was not detected in human and mouse monocytes and macrophages, suggesting that the effects of bioactive compounds on stimulator of interferon genes (STING) activation may not depend on ALK.

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：

Year: 2018 PMID： 30541790 PMCID： PMC6459396 DOI： 10.1126/scitranslmed.aar4321

Source DB: PubMed Journal: Sci Transl Med ISSN： 1946-6234 Impact factor: 17.956

Keyword Cloud
References

11 in total

1. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)

Authors: S W Morris; C Naeve; P Mathew; P L James; M N Kirstein; X Cui; D P Witte
Journal: Oncogene Date: 1997-05-08 Impact factor: 9.867

2. Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin.

Authors: Christel Moog-Lutz; Joffrey Degoutin; Jean Y Gouzi; Yvelyne Frobert; Nicole Brunet-de Carvalho; Jocelyne Bureau; Christophe Créminon; Marc Vigny
Journal: J Biol Chem Date: 2005-05-10 Impact factor: 5.157

3. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system.

Authors: T Iwahara; J Fujimoto; D Wen; R Cupples; N Bucay; T Arakawa; S Mori; B Ratzkin; T Yamamoto
Journal: Oncogene Date: 1997-01-30 Impact factor: 9.867

4. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials.

Authors: Thomas H Marsilje; Wei Pei; Bei Chen; Wenshuo Lu; Tetsuo Uno; Yunho Jin; Tao Jiang; Sungjoon Kim; Nanxin Li; Markus Warmuth; Yelena Sarkisova; Frank Sun; Auzon Steffy; AnneMarie C Pferdekamper; Allen G Li; Sean B Joseph; Young Kim; Bo Liu; Tove Tuntland; Xiaoming Cui; Nathanael S Gray; Ruo Steensma; Yongqin Wan; Jiqing Jiang; Greg Chopiuk; Jie Li; W Perry Gordon; Wendy Richmond; Kevin Johnson; Jonathan Chang; Todd Groessl; You-Qun He; Andrew Phimister; Alex Aycinena; Christian C Lee; Badry Bursulaya; Donald S Karanewsky; H Martin Seidel; Jennifer L Harris; Pierre-Yves Michellys
Journal: J Med Chem Date: 2013-06-26 Impact factor: 7.446

5. ALK is a therapeutic target for lethal sepsis.

Authors: Ling Zeng; Rui Kang; Shan Zhu; Xiao Wang; Lizhi Cao; Haichao Wang; Timothy R Billiar; Jianxin Jiang; Daolin Tang
Journal: Sci Transl Med Date: 2017-10-18 Impact factor: 17.956

Review 6. The anaplastic lymphoma kinase in the pathogenesis of cancer.

Authors: Roberto Chiarle; Claudia Voena; Chiara Ambrogio; Roberto Piva; Giorgio Inghirami
Journal: Nat Rev Cancer Date: 2008-01 Impact factor: 60.716

7. Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.

Authors: Wei-Sheng Huang; Shuangying Liu; Dong Zou; Mathew Thomas; Yihan Wang; Tianjun Zhou; Jan Romero; Anna Kohlmann; Feng Li; Jiwei Qi; Lisi Cai; Timothy A Dwight; Yongjin Xu; Rongsong Xu; Rory Dodd; Angela Toms; Lois Parillon; Xiaohui Lu; Rana Anjum; Sen Zhang; Frank Wang; Jeffrey Keats; Scott D Wardwell; Yaoyu Ning; Qihong Xu; Lauren E Moran; Qurish K Mohemmad; Hyun Gyung Jang; Tim Clackson; Narayana I Narasimhan; Victor M Rivera; Xiaotian Zhu; David Dalgarno; William C Shakespeare
Journal: J Med Chem Date: 2016-05-12 Impact factor: 7.446